Seminal
The magazine and atlas of EU-funded researchA new publication from the web and AI team at Scott Charnley

Atlas / Belgium

European Research Council grant · Running

EicoMet Targeting eicosanoid metabolism to overcome tumor immunosuppression

Coordinator
Vib Vzw, Belgium
Runs
1 February 2024 to 31 July 2025
Status
Running
EU funding
€150k
Total cost
—
Partners
1 organisations in 1 countries
Type
European Research Council grant
Grant agreement
101123280

What the project is doing

In the project's own words, from its summary on CORDIS.

The field of cancer immunotherapy has witnessed exciting therapeutic advances in the last decade, but still a large fraction of patients is not responsive and several cancer types are refractory to this therapy. The presence of a strongly immunosuppressive environment is a likely explanation for the suboptimal efficacy of immunotherapy. One of the most abundant and immune suppressive population in the tumor microenvironment (TME) is represented by tumor-associated macrophages (TAMs).

Therefore, several strategies that sculpt the TAM phenotype away from their immunosuppressive state are expected to become the next generation immunotherapies. Supported by the ERC consolidator grant ImmunoFit, we recently unveiled that the metabolic editing of the TME via the pharmacological and genetic inhibition of HPGDS in macrophages (an enzyme involved in the production of prostaglandin D2 from arachidonic acid), represents a novel therapeutic strategy to sculpt TAMs away from their immunosuppressive state, increase infiltration and fitness of CD8+ T cells and NK cells, and promote tumor vessel normalization.

This change in the TME upon HPGDS inhibition overcomes resistance to current immunotherapeutic regimens in melanoma and other cancer indications. This proposal aims to de-risk HPGDS targeting by delivering a lead compound with proven efficacy in several preclinical models. The deliverables of this project will open-up a window of opportunities in immune-oncology and lead to novel combination therapies by increasing the potency of the current therapeutic approaches.

Topics

Who is involved

OrganisationCityCountryRole
Vib VzwZwijnaarde - GentBelgiumCoordinator

Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI